Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus

Esteban J. Estrada, Fabian Valacchi, Eduardo Nicora, Sergio Brieva, Claudio Esteve, Laura Echevarria, Tatiana Froud, Karina Bernetti, Shari Messinger, Omaida C Velazquez, Rodolfo Alejandro, Camillo Ricordi

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The objective of this study was to determine whether the combination therapy of intrapancreatic autologous stem cell infusion (ASC) and hyperbaric oxygen treatment (HBO) before and after ASC can improve islet function and metabolic control in patients with type 2 diabetes mellitus (T2DM). This prospective phase 1 study enrolled 25 patients with T2DM who received a combination therapy of intrapancreatic ASC and peri-infusion HBO between March 2004 and October 2006 at Stem Cells Argentina Medical Center Buenos Aires, Argentina. Clinical variables (body mass index, oral hypoglycemic drugs, insulin requirement) and metabolic variables (fasting plasma glucose, C-peptide, HbA1c, and calculation of C-peptide/glucose ratio) were assessed over quartile periods starting at baseline and up to 1 year follow-up after intervention. Means were calculated in each quartile period and compared to baseline. Seventeen male and eight female patients were enrolled. Baseline variables expressed as means ± SEs were: age 55 ± 2.14 years, diabetes duration 13.2+1.62 years, insulin dose 34.8 + 2.96 U/day, and BMI 27.11 ± 0.51. All metabolic variables showed significant improvement when comparing baseline to 12 months follow-up, respectively: fasting glucose 205.6 ± 5.9 versus 105.2 ± 14.2 mg/dl, HbA1c 8.8 ± 0.2 versus 6.0 ± 0.4%, fasting C-peptide 1.5 ± 0.2 versus 3.3 ± 0.3 ng/ml, C-peptide/glucose ratio 0.7 ± 0.2 versus 3.5 ± 0.3, and insulin requirements 34.8 ± 2.9 versus 2.5 ± 6.7 U/day. BMI remained constant over the 1-year follow-up. Combined therapy of intrapancreatic ASC infusion and HBO can improve metabolic control and reduce insulin requirements in patients with T2DM. Further randomized controlled clinical trials will be required to confirm these findings.

Original languageEnglish
Pages (from-to)1295-1304
Number of pages10
JournalCell Transplantation
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2008

Fingerprint

Medical problems
Stem cells
Bone Marrow Cells
Type 2 Diabetes Mellitus
Insulin
Bone
Stem Cells
C-Peptide
Peptides
Glucose
Oxygen
Fasting
Argentina
Therapeutics
Hypoglycemic Agents
Body Mass Index
Plasmas
Randomized Controlled Trials

Keywords

  • Autologous transplant
  • Hyperbaric oxygen
  • Stem cell
  • Type 2 diabetes

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. / Estrada, Esteban J.; Valacchi, Fabian; Nicora, Eduardo; Brieva, Sergio; Esteve, Claudio; Echevarria, Laura; Froud, Tatiana; Bernetti, Karina; Messinger, Shari; Velazquez, Omaida C; Alejandro, Rodolfo; Ricordi, Camillo.

In: Cell Transplantation, Vol. 17, No. 12, 01.12.2008, p. 1295-1304.

Research output: Contribution to journalArticle

Estrada, Esteban J. ; Valacchi, Fabian ; Nicora, Eduardo ; Brieva, Sergio ; Esteve, Claudio ; Echevarria, Laura ; Froud, Tatiana ; Bernetti, Karina ; Messinger, Shari ; Velazquez, Omaida C ; Alejandro, Rodolfo ; Ricordi, Camillo. / Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. In: Cell Transplantation. 2008 ; Vol. 17, No. 12. pp. 1295-1304.
@article{0f8ffcfc7ce54844b5062d4de8adf30a,
title = "Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus",
abstract = "The objective of this study was to determine whether the combination therapy of intrapancreatic autologous stem cell infusion (ASC) and hyperbaric oxygen treatment (HBO) before and after ASC can improve islet function and metabolic control in patients with type 2 diabetes mellitus (T2DM). This prospective phase 1 study enrolled 25 patients with T2DM who received a combination therapy of intrapancreatic ASC and peri-infusion HBO between March 2004 and October 2006 at Stem Cells Argentina Medical Center Buenos Aires, Argentina. Clinical variables (body mass index, oral hypoglycemic drugs, insulin requirement) and metabolic variables (fasting plasma glucose, C-peptide, HbA1c, and calculation of C-peptide/glucose ratio) were assessed over quartile periods starting at baseline and up to 1 year follow-up after intervention. Means were calculated in each quartile period and compared to baseline. Seventeen male and eight female patients were enrolled. Baseline variables expressed as means ± SEs were: age 55 ± 2.14 years, diabetes duration 13.2+1.62 years, insulin dose 34.8 + 2.96 U/day, and BMI 27.11 ± 0.51. All metabolic variables showed significant improvement when comparing baseline to 12 months follow-up, respectively: fasting glucose 205.6 ± 5.9 versus 105.2 ± 14.2 mg/dl, HbA1c 8.8 ± 0.2 versus 6.0 ± 0.4{\%}, fasting C-peptide 1.5 ± 0.2 versus 3.3 ± 0.3 ng/ml, C-peptide/glucose ratio 0.7 ± 0.2 versus 3.5 ± 0.3, and insulin requirements 34.8 ± 2.9 versus 2.5 ± 6.7 U/day. BMI remained constant over the 1-year follow-up. Combined therapy of intrapancreatic ASC infusion and HBO can improve metabolic control and reduce insulin requirements in patients with T2DM. Further randomized controlled clinical trials will be required to confirm these findings.",
keywords = "Autologous transplant, Hyperbaric oxygen, Stem cell, Type 2 diabetes",
author = "Estrada, {Esteban J.} and Fabian Valacchi and Eduardo Nicora and Sergio Brieva and Claudio Esteve and Laura Echevarria and Tatiana Froud and Karina Bernetti and Shari Messinger and Velazquez, {Omaida C} and Rodolfo Alejandro and Camillo Ricordi",
year = "2008",
month = "12",
day = "1",
doi = "10.3727/096368908787648119",
language = "English",
volume = "17",
pages = "1295--1304",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "12",

}

TY - JOUR

T1 - Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus

AU - Estrada, Esteban J.

AU - Valacchi, Fabian

AU - Nicora, Eduardo

AU - Brieva, Sergio

AU - Esteve, Claudio

AU - Echevarria, Laura

AU - Froud, Tatiana

AU - Bernetti, Karina

AU - Messinger, Shari

AU - Velazquez, Omaida C

AU - Alejandro, Rodolfo

AU - Ricordi, Camillo

PY - 2008/12/1

Y1 - 2008/12/1

N2 - The objective of this study was to determine whether the combination therapy of intrapancreatic autologous stem cell infusion (ASC) and hyperbaric oxygen treatment (HBO) before and after ASC can improve islet function and metabolic control in patients with type 2 diabetes mellitus (T2DM). This prospective phase 1 study enrolled 25 patients with T2DM who received a combination therapy of intrapancreatic ASC and peri-infusion HBO between March 2004 and October 2006 at Stem Cells Argentina Medical Center Buenos Aires, Argentina. Clinical variables (body mass index, oral hypoglycemic drugs, insulin requirement) and metabolic variables (fasting plasma glucose, C-peptide, HbA1c, and calculation of C-peptide/glucose ratio) were assessed over quartile periods starting at baseline and up to 1 year follow-up after intervention. Means were calculated in each quartile period and compared to baseline. Seventeen male and eight female patients were enrolled. Baseline variables expressed as means ± SEs were: age 55 ± 2.14 years, diabetes duration 13.2+1.62 years, insulin dose 34.8 + 2.96 U/day, and BMI 27.11 ± 0.51. All metabolic variables showed significant improvement when comparing baseline to 12 months follow-up, respectively: fasting glucose 205.6 ± 5.9 versus 105.2 ± 14.2 mg/dl, HbA1c 8.8 ± 0.2 versus 6.0 ± 0.4%, fasting C-peptide 1.5 ± 0.2 versus 3.3 ± 0.3 ng/ml, C-peptide/glucose ratio 0.7 ± 0.2 versus 3.5 ± 0.3, and insulin requirements 34.8 ± 2.9 versus 2.5 ± 6.7 U/day. BMI remained constant over the 1-year follow-up. Combined therapy of intrapancreatic ASC infusion and HBO can improve metabolic control and reduce insulin requirements in patients with T2DM. Further randomized controlled clinical trials will be required to confirm these findings.

AB - The objective of this study was to determine whether the combination therapy of intrapancreatic autologous stem cell infusion (ASC) and hyperbaric oxygen treatment (HBO) before and after ASC can improve islet function and metabolic control in patients with type 2 diabetes mellitus (T2DM). This prospective phase 1 study enrolled 25 patients with T2DM who received a combination therapy of intrapancreatic ASC and peri-infusion HBO between March 2004 and October 2006 at Stem Cells Argentina Medical Center Buenos Aires, Argentina. Clinical variables (body mass index, oral hypoglycemic drugs, insulin requirement) and metabolic variables (fasting plasma glucose, C-peptide, HbA1c, and calculation of C-peptide/glucose ratio) were assessed over quartile periods starting at baseline and up to 1 year follow-up after intervention. Means were calculated in each quartile period and compared to baseline. Seventeen male and eight female patients were enrolled. Baseline variables expressed as means ± SEs were: age 55 ± 2.14 years, diabetes duration 13.2+1.62 years, insulin dose 34.8 + 2.96 U/day, and BMI 27.11 ± 0.51. All metabolic variables showed significant improvement when comparing baseline to 12 months follow-up, respectively: fasting glucose 205.6 ± 5.9 versus 105.2 ± 14.2 mg/dl, HbA1c 8.8 ± 0.2 versus 6.0 ± 0.4%, fasting C-peptide 1.5 ± 0.2 versus 3.3 ± 0.3 ng/ml, C-peptide/glucose ratio 0.7 ± 0.2 versus 3.5 ± 0.3, and insulin requirements 34.8 ± 2.9 versus 2.5 ± 6.7 U/day. BMI remained constant over the 1-year follow-up. Combined therapy of intrapancreatic ASC infusion and HBO can improve metabolic control and reduce insulin requirements in patients with T2DM. Further randomized controlled clinical trials will be required to confirm these findings.

KW - Autologous transplant

KW - Hyperbaric oxygen

KW - Stem cell

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=62549123720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549123720&partnerID=8YFLogxK

U2 - 10.3727/096368908787648119

DO - 10.3727/096368908787648119

M3 - Article

VL - 17

SP - 1295

EP - 1304

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 12

ER -